Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Portola Pharmaceuticals nets $131mm in initial public offering

Executive Summary

Portola Pharmaceuticals Inc. (hematological and inflammatory disorders) has netted $131mm in its initial public offering. The company ended up selling 9.7mm shares (including the overallotment)--more than the 6.9mm planned--and priced the stock at $14.50, the mid-point of its $13-16 range.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies